Aifa report: 16 serious events every 100 thousand vaccine doses
The Italian drug agency Aifa has published the seventh Pharmacovigilance Report on Covid-19 Vaccines. The data collected and analyzed concern the reports of suspected adverse reactions registered in the National Pharmacovigilance Network between 27 December 2020 and 26 July 2021 for the four vaccines in use in the current vaccination campaign. In the period considered, 84,322 reports were received out of a total of 65,926,591 doses administered (reporting rate of 128 per 100,000 doses), of which 87.1% referred to non-serious events, such as pain at the injection site, fever, asthenia / fatigue, muscle aches. Serious reports correspond to 12.8% of the total, with a rate of 16 serious events per 100,000 doses administered.
In detail, the most often reported serious adverse events related to vaccination configure a picture of flu-like syndrome with intense symptoms, more frequent after the second dose of mRNA vaccines and after the first dose of Vaxzevria. As reported in previous Reports, regardless of the vaccine, dose and type of event, the reaction occurred in most cases (about 80%) on the same day of vaccination or the next day and only more rarely beyond 48 hours. following. Most of the reports are related to the Pfizer Biontech Comirnaty vaccine (68%), so far the most used in the vaccination campaign (71% of the doses administered) and only to a lesser extent to the Vaxzevria vaccine by Astrazeneca (25% of the reports and 17% doses administered), Moderna’s Spikevax vaccine (6% of reports and 10% of doses administered) and Johnson and Johnson’s COVID-19 Janssen vaccine (1% of reports and 2% of doses administered).
–
